Journal of the American Academy of Dermatology

NEW STUDY REVEALS THAT SOME CHILDREN WITH COMMON FORM OF ECZEMA SHOULD ALSO BE TESTED FOR ALLERGIC REACTIONS

Retrieved on: 
Tuesday, September 26, 2023
Allergy, Jiading District, Arm, University, Metal, Face, Skin care, JAK, University of California, San Francisco, Allergic contact dermatitis, Table tennis rubber, Journal of the American Academy of Dermatology, American Academy, Atopic dermatitis, Cosmetics, Inflammation, FAAD, Light, Journal, Nickel, Child, Immune system, Jeff, Steroid, Diagnosis, Hospital, Patient, Massachusetts General Hospital, Skin, Dietary supplement, Perfume, Dermatitis, Dermatology, MD

ROSEMONT, Ill., Sept. 26, 2023 /PRNewswire/ -- Eczema, which is a group of medical conditions that causes inflamed, irritated, and often itchy skin, affects millions of people worldwide. A new article published in the Journal of the American Academy of Dermatology reveals that children diagnosed with a type of eczema called atopic dermatitis – which they usually develop by 5 years of age – may also need to be tested for a second type of eczema called allergic contact dermatitis, which has similar symptoms and can be triggered by a range of substances that cause an allergic reaction.

Key Points: 
  • "It turns out that most of the things that I'm allergic to are very common ingredients in a lot of products," Schoeben said.
  • Poison ivy, poison oak and poison sumac are the most common causes of allergic reactions in the United States.
  • Other common causes of allergic contact dermatitis include metals (such as nickel), rubber, dyes, cosmetics, preservatives, and fragrances.
  • In these cases, the overall eczema may look very severe but once you remove the allergic component, the eczema seems much more manageable.

NEW TREATMENTS PROVIDE MORE OPTIONS FOR PEOPLE WITH ALOPECIA AREATA

Retrieved on: 
Tuesday, August 15, 2023
Hair, Asthma, University, Eyelash, Hair loss, JAK, Medicine, Dermatitis, University of Arkansas for Medical Sciences, Marten, Silver, Immunodeficiency, Cancer, Clinical trial, Nail, Journal of the American Academy of Dermatology, Hope, Head, Methotrexate, American Academy, Inflammation, FAAD, Scalp, Down syndrome, Alopecia areata, Eyebrow, Journal, MD, Patient, Immune system, Thyroid disease, DR, Vitiligo, Nivolumab, Disease, Pharmaceutical industry, Medical device, Dermatology

ROSEMONT, Ill., Aug. 15, 2023 /PRNewswire/ -- A study published today in a supplement of the Journal of the American Academy of Dermatology titled "Alopecia: A New Frontier" reveals that a new type of medication called JAK inhibitors can effectively treat moderate to severe alopecia areata – a type of hair loss – that has historically been difficult to treat.

Key Points: 
  • "The development of JAK inhibitors has given us another treatment to improve the lives of patients with alopecia areata."
  • The most common sign of alopecia areata is often sudden hair loss, Dr. Johnson said.
  • Having other medical conditions such as asthma, hay fever, eczema, thyroid disease, vitiligo, and Down syndrome also increases a person's risks for developing alopecia areata.
  • "We now have more treatment options than ever before for alopecia areata patients, and they are providing results for people for whom previous treatments were not effective," said Dr. Johnson.

Hair Loss Drug Can be Deadly to Pets

Retrieved on: 
Wednesday, August 9, 2023
Blood pressure, Hair, Journal of the American Academy of Dermatology, Argyreia nervosa, Vomiting, Minoxidil, Hair loss, Gastrointestinal tract, Hypotension, Dog, Pet, Hypothermia, American Academy, War, Cat, Cyanosis, Human, Animal, Pleural effusion, Poisoning, Lethargy, Water, Child, Periodic breathing, Broadway, Observation, Heart rate, Pulmonary edema, Medical imaging, Birth control

MINNEAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Humans are obsessed with hair. We have entire industries dedicated to growing it, losing it, regrowing it, artificially replacing it, washing it, cutting it, coloring it, shaving it, waxing it, styling it, covering it and photographing it. We even have a smash Broadway musical celebrating it.

Key Points: 
  • Perhaps the biggest holy grail in the hair care industry is a cure for baldness.
  • According to the American Academy of Dermatology, more than 80 million Americans suffer from hair loss.
  • In honor of National Hair Loss Awareness Month in August, the toxicology experts at Pet Poison Helpline want to warn hair-loss medication users how dangerous it can be to pets.
  • "Products like Rogaine®, which contain the medication minoxidil , have helped many people with hair loss," said Dr. Renee Schmid, a senior veterinary toxicologist at Pet Poison Helpline.

LARGEST STUDY ON RACIAL DIFFERENCES IN MEN WITH MELANOMA SHOWS MEN WITH SKIN OF COLOR HAVE LOWEST SURVIVAL RATES

Retrieved on: 
Tuesday, July 11, 2023
Survival rate, Melanoma, Extremities, University, Social conditions in Honduras, Bleeding, University of Nebraska Medical Center, DIAMETER, Survival, Skin cancer, Truth: Red, White & Black, Nail, Journal of the American Academy of Dermatology, Woman, American Academy, Nebraska Medicine, Research, Factorization of polynomials, FAAD, Hormone, Journal, MD, Patient, Immune system, COLOR, Diagnosis, Health, Death, Rest, Skin, Medical imaging, Silviculture, Dermatology, Black, White

ROSEMONT, Ill., July 11, 2023 /PRNewswire/ -- Melanoma, the most serious form of skin cancer, is highly treatable when detected early, but when the disease advances, it can lead to death. A new article published in the Journal of the American Academy of Dermatology reveals that men with melanoma – and particularly men with skin of color – are more likely to die than women with melanoma.

Key Points: 
  • A new article published in the Journal of the American Academy of Dermatology reveals that men with melanoma – and particularly men with skin of color – are more likely to die than women with melanoma.
  • The analysis involved more than 200,000 participants and is the largest study to date on racial differences in men with melanoma.
  • It compared melanoma diagnosis data from the National Cancer Database from 2004 until 2018 in White, Black, Asian, American Indian/Alaskan Native, and Hispanic men.
  • Overall survival rates in men with melanoma were highest for White men (75 percent), followed by American Indian/Alaskan Native (69 percent), Asian (68 percent), Hispanic (66 percent), and Black men (52 percent).

Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team

Retrieved on: 
Wednesday, June 28, 2023
Drug development, University, Dermatitis, Drug, Journal of the American Academy of Dermatology, American Academy, Acne, Bristol Myers Squibb, Lupus, Psoriasis, Caritas in veritate, Eli Lilly, JAMA Dermatology, UCB, Baylor University, Journal, Publication, Novartis, Series, University of Louisville School of Medicine, Clinical, Drug reaction with eosinophilia and systemic symptoms, Inflammation, Pharmaceutical industry, Medicine, Dermatology, MD, Pfizer

PALO ALTO, Calif., June 28, 2023 /PRNewswire/ -- Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the closing of an additional $7.5 million to its Series B financing from new investor Verition Fund Management, bringing the total raised in the Series B round to $57.5 million. The company previously announced the closing of the initial $50 million in April 2023. In addition, the company also announced the appointment of J. Mark Jackson, MD, as Vice President, Clinical Development. 

Key Points: 
  • The company previously announced the closing of the initial $50 million in April 2023.
  • We are also very pleased Dr. Jackson is joining our organization in a key clinical leadership position.
  • Dr. Jackson joins Evommune from his position as a Clinical Professor of Medicine at the University of Louisville.
  • Dr. Jackson received his undergraduate degree from Baylor University and his medical degree from Texas A&M College of Medicine.

NIAAA: Risky Drinking Can Put a Chill on Your Summer Fun

Retrieved on: 
Monday, June 12, 2023
Systematic review, Snack, Siderian, Accident, Friends, United States Department of Homeland Security, National Institute on Alcohol Abuse and Alcoholism, Dehydration, Hypothermia, National Association, Urination, Skin cancer, BAC, Risk, Multimedia, Volume, Heat stroke, Meta-analysis, Drinking, CDC, United States Coast Guard, Internet, U.S. Coast Guard Station, Death, Crash, National Safety Council, Swimming, Korea Disease Control and Prevention Agency, Water, Pet, PubMed, Legal drinking age, Bariatric surgery, Wilderness, Sunburn, Journal of the American Academy of Dermatology, Health, Transport, Perspiration, Family, News, NIAAA, Skin, Fatigue, JAMA, Liquor, Beer, Propane, Alcoholism

This summer, take measures to protect your own health and that of your loved ones.

Key Points: 
  • This summer, take measures to protect your own health and that of your loved ones.
  • Individual factors such as drinking on an empty stomach may influence how quickly someone reaches a 0.08% BAC.
  • The summer holidays are some of the most dangerous times of the year to be on the road.
  • Whether drinking or not, be sure to slather on the sunscreen to maximize your summer fun!

Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results

Retrieved on: 
Friday, March 31, 2023
Clinical and Experimental Dermatology, Civil service commission, Intellectual property, Commission, CI, Clinical trial, XLRI, Skin, American Academy, Fast Track, Sale, Breakthrough therapy, Journal of the American Academy of Dermatology, Ichthyosis, ASCEND, CONTROL, Patient, X-linked ichthyosis, Security (finance), Isotretinoin, FDA, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, European Commission, ARCI, Pharmaceutical industry, Cryptocurrency, Dermatology, Lumber

WARREN, NJ, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • John Koconis, Chairman and Chief Executive Officer of Timber, commented, “Timber had an exciting year in 2022 and achieved several significant milestones.
  • These designations, combined with the positive Phase 2b results, are assisting in our Phase 3 ASCEND clinical trial recruitment, which has now reached 50%.
  • In Spring 2022, Timber received Breakthrough Therapy designation and Fast Track designation from the FDA for TMB-001.
  • For Timber’s complete financial results for the fourth quarter and year ended December 31, 2022, see the Company’s Annual Form 10-K filed with the Securities and Exchange Commission on March 31, 2023.

Longest Running Real World Dermatology Registry, TARGET-DERM, Offers Deep Insight into Complex Diseases

Retrieved on: 
Tuesday, February 28, 2023
PROMIS, Skin, MSCE, AA, DLQI, Doctor of Philosophy, Quality of life, Saliva, White, AAD, American Academy, PRO, Atopic dermatitis, Associate, NRS, Chairperson, Research, Journal, Patient, Hope, IRB, Plasma, Hidradenitis suppurativa, TARGET, HS, Adolescence, Roger Hawkins (drummer), Serum, Journal of the American Academy of Dermatology, AD, Alopecia areata, MA, RWE, Environmental remediation, Dietary supplement, Medical device, Medical imaging, MD, Gastroenterology, Rheumatology, Dermatology

The TARGET-DERM community has more than 4,000 participants enrolled today, across 34 sites in the U.S. and Canada.

Key Points: 
  • The TARGET-DERM community has more than 4,000 participants enrolled today, across 34 sites in the U.S. and Canada.
  • Target RWE recently announced the launch of 35 new disease state registries , which includes the entire spectrum of immune-mediated inflammatory conditions: Dermatology, Gastroenterology, and Rheumatology, to capture valuable real world patient data to better understand these complex conditions.
  • Today, the TARGET-DERM community enrolls patients with atopic dermatitis (AD), hidradenitis suppurativa, chronic spontaneous urticaria, and alopecia areata.
  • Over the past several years, we have been able to take a deep dive into highly disruptive skin conditions to gain better perspective on the autoimmune dermatology landscape.

Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Friday, January 27, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Ministry of Health, Bristol Myers Squibb, TYK2, European Commission, Journal, CHMP, Light, Apremilast, NYSE, Lower respiratory tract infection, Civil service commission, Patient, Face, Committee, Skin, Folliculitis, Food, Ministry, BMY, Committee for Medicinal Products for Human Use, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American Academy, FDA, Journal of the American Academy of Dermatology, Ministry of Health, Labour and Welfare, Quality of life, Psoriasis, European, PSO, MD, Pharmaceutical industry, Deucravacitinib, EU

Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.
  • Sotyktu, an oral medication taken once-daily, is a first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.
  • The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union (EU).
  • Bristol Myers Squibb thanks the patients and investigators involved in the POETYK PSO clinical trial program.

Nogra Pharma announces out-licensing agreement with Torii Pharmaceutical for Japan for New Chemical Entity topical acne treatment

Retrieved on: 
Thursday, January 26, 2023
Standard of care, Prevalence, Journal of the American Academy of Dermatology, NCE, British Journal of Dermatology, New chemical entity, Therapy, Keratinocyte, Skin, Patient, EudraCT, Acne, Nogra, Epidemiology, Adolescence, IGA, Medical device, Pharmaceutical industry, Dermatology

Under the agreement, [for which financial terms are not being disclosed], Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan.

Key Points: 
  • Under the agreement, [for which financial terms are not being disclosed], Torii Pharmaceuticals will gain exclusive development and commercialisation rights for NAC-GED-0507 in Japan.
  • NAC-GED-0507 is an IP protected, Phase III-ready, small molecule selective modulator of the peroxisome proliferation-activated receptor γ (PPARγ), which has been developed by Nogra Pharma in a gel formulation, ideal for topical treatment of acne vulgaris.
  • Leopoldo Zambeletti, Director of Nogra Pharma Ltd, commented: “The agreement with Torii Pharmaceuticals is a testament to the high quality of our scientific network and our development and formulation expertise.
  • Given the promising clinical data, we are confident that NAC-GED-0507 will provide a new treatment option for acne patients.